Publications from Australia

   
____________________________________________________________________________________________ The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early
October 2010, ASH 2010
________________________________________________________________________________________
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
September 2010, Nature.com
_________________________________________________________________________________________